Third, there is a possibility of underestimating the incidence of leukopenia and G-CSF administration related to ATD because we excluded patients with three malignancies for which G-CSF commonly used, and some of these patients had both ATD and G-CSF treatment. This evidence concerns the gene CSF3 and Decreased total leukocyte count.